Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure
Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure Roland R. van Kimmenade, James L. Januzzi, Jr, Patrick T. Ellinor, Umesh C. Sharma, Jaap A. Bakker, Adrian F. Low, Abelardo Martinez, Harry J. Crijns, Calum A. MacR...
Saved in:
| Published in | Journal of the American College of Cardiology Vol. 48; no. 6; pp. 1217 - 1224 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York, NY
Elsevier Inc
19.09.2006
Elsevier Science Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure
Roland R. van Kimmenade, James L. Januzzi, Jr, Patrick T. Ellinor, Umesh C. Sharma, Jaap A. Bakker, Adrian F. Low, Abelardo Martinez, Harry J. Crijns, Calum A. MacRae, Paul P. Menheere, Yigal M. Pinto
This study investigated the utility of apelin and galectin-3 alone or together with amino-terminal pro-brain natriuretic peptide (NT-proBNP) for short-term prognosis in acute heart failure (HF). Serum concentrations were measured in 599 patients presenting with dyspnea at the emergency department, of which 209 (35%) had acute HF. Receiver operating characteristic analysis showed that galectin-3 had the greatest area under the curve (AUC) for prognosis (AUC = 0.74) when compared with NT-proBNP and apelin (AUC = 0.67 and 0.54). An elevated level of galectin-3 was the best independent predictor of death/recurrent HF within 60 days (odds ratio 14.3, p < 0.001), but the combination of elevated galectin-3 and NT-proBNP was an even stronger predictor.
This study sought to explore the role of new biomarkers in heart failure (HF).
We investigated the utility of novel serum markers alone or together with natriuretic peptide testing for diagnosis and short-term prognosis estimation in subjects with acute HF.
Plasma levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP), apelin, and galectin-3 were measured in 599 patients presenting with dyspnea at the emergency department, of which 209 (35%) had acute HF.
The NT-proBNP was superior to either apelin or galectin-3 for diagnosis of acute HF, although galectin-3 levels were significantly higher in subjects with HF compared with those without. Receiver operating characteristic analysis for mortality prediction showed that, for 60-day prognosis, galectin-3 had the greatest area under the curve (AUC) at 0.74 (p = 0.0001), whereas NT-proBNP and apelin had an AUC of 0.67 (p = 0.009) and 0.54 (p = 0.33). In a multivariate logistic regression analysis, an elevated level of galectin-3 was the best independent predictor of 60-day mortality (odds ratio 10.3, p < 0.01) or the combination of death/recurrent HF within 60 days (odds ratio 14.3, p < 0.001). The Kaplan-Meier analyses showed that the combination of an elevated galectin-3 with NT-proBNP was a better predictor of mortality than either of the 2 markers alone.
Our data show potential utility of galectin-3 as a useful marker for evaluation of patients with suspected or proven acute HF, whereas apelin measurement was not useful for these indications. Moreover, the combination of galectin-3 with NT-proBNP was the best predictor for prognosis in subjects with acute HF. |
|---|---|
| AbstractList | This study sought to explore the role of new biomarkers in heart failure (HF).
We investigated the utility of novel serum markers alone or together with natriuretic peptide testing for diagnosis and short-term prognosis estimation in subjects with acute HF.
Plasma levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP), apelin, and galectin-3 were measured in 599 patients presenting with dyspnea at the emergency department, of which 209 (35%) had acute HF.
The NT-proBNP was superior to either apelin or galectin-3 for diagnosis of acute HF, although galectin-3 levels were significantly higher in subjects with HF compared with those without. Receiver operating characteristic analysis for mortality prediction showed that, for 60-day prognosis, galectin-3 had the greatest area under the curve (AUC) at 0.74 (p = 0.0001), whereas NT-proBNP and apelin had an AUC of 0.67 (p = 0.009) and 0.54 (p = 0.33). In a multivariate logistic regression analysis, an elevated level of galectin-3 was the best independent predictor of 60-day mortality (odds ratio 10.3, p < 0.01) or the combination of death/recurrent HF within 60 days (odds ratio 14.3, p < 0.001). The Kaplan-Meier analyses showed that the combination of an elevated galectin-3 with NT-proBNP was a better predictor of mortality than either of the 2 markers alone.
Our data show potential utility of galectin-3 as a useful marker for evaluation of patients with suspected or proven acute HF, whereas apelin measurement was not useful for these indications. Moreover, the combination of galectin-3 with NT-proBNP was the best predictor for prognosis in subjects with acute HF. Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure Roland R. van Kimmenade, James L. Januzzi, Jr, Patrick T. Ellinor, Umesh C. Sharma, Jaap A. Bakker, Adrian F. Low, Abelardo Martinez, Harry J. Crijns, Calum A. MacRae, Paul P. Menheere, Yigal M. Pinto This study investigated the utility of apelin and galectin-3 alone or together with amino-terminal pro-brain natriuretic peptide (NT-proBNP) for short-term prognosis in acute heart failure (HF). Serum concentrations were measured in 599 patients presenting with dyspnea at the emergency department, of which 209 (35%) had acute HF. Receiver operating characteristic analysis showed that galectin-3 had the greatest area under the curve (AUC) for prognosis (AUC = 0.74) when compared with NT-proBNP and apelin (AUC = 0.67 and 0.54). An elevated level of galectin-3 was the best independent predictor of death/recurrent HF within 60 days (odds ratio 14.3, p < 0.001), but the combination of elevated galectin-3 and NT-proBNP was an even stronger predictor. Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure Roland R. van Kimmenade, James L. Januzzi, Jr, Patrick T. Ellinor, Umesh C. Sharma, Jaap A. Bakker, Adrian F. Low, Abelardo Martinez, Harry J. Crijns, Calum A. MacRae, Paul P. Menheere, Yigal M. Pinto This study investigated the utility of apelin and galectin-3 alone or together with amino-terminal pro-brain natriuretic peptide (NT-proBNP) for short-term prognosis in acute heart failure (HF). Serum concentrations were measured in 599 patients presenting with dyspnea at the emergency department, of which 209 (35%) had acute HF. Receiver operating characteristic analysis showed that galectin-3 had the greatest area under the curve (AUC) for prognosis (AUC = 0.74) when compared with NT-proBNP and apelin (AUC = 0.67 and 0.54). An elevated level of galectin-3 was the best independent predictor of death/recurrent HF within 60 days (odds ratio 14.3, p < 0.001), but the combination of elevated galectin-3 and NT-proBNP was an even stronger predictor. This study sought to explore the role of new biomarkers in heart failure (HF). We investigated the utility of novel serum markers alone or together with natriuretic peptide testing for diagnosis and short-term prognosis estimation in subjects with acute HF. Plasma levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP), apelin, and galectin-3 were measured in 599 patients presenting with dyspnea at the emergency department, of which 209 (35%) had acute HF. The NT-proBNP was superior to either apelin or galectin-3 for diagnosis of acute HF, although galectin-3 levels were significantly higher in subjects with HF compared with those without. Receiver operating characteristic analysis for mortality prediction showed that, for 60-day prognosis, galectin-3 had the greatest area under the curve (AUC) at 0.74 (p = 0.0001), whereas NT-proBNP and apelin had an AUC of 0.67 (p = 0.009) and 0.54 (p = 0.33). In a multivariate logistic regression analysis, an elevated level of galectin-3 was the best independent predictor of 60-day mortality (odds ratio 10.3, p < 0.01) or the combination of death/recurrent HF within 60 days (odds ratio 14.3, p < 0.001). The Kaplan-Meier analyses showed that the combination of an elevated galectin-3 with NT-proBNP was a better predictor of mortality than either of the 2 markers alone. Our data show potential utility of galectin-3 as a useful marker for evaluation of patients with suspected or proven acute HF, whereas apelin measurement was not useful for these indications. Moreover, the combination of galectin-3 with NT-proBNP was the best predictor for prognosis in subjects with acute HF. This study sought to explore the role of new biomarkers in heart failure (HF).OBJECTIVESThis study sought to explore the role of new biomarkers in heart failure (HF).We investigated the utility of novel serum markers alone or together with natriuretic peptide testing for diagnosis and short-term prognosis estimation in subjects with acute HF.BACKGROUNDWe investigated the utility of novel serum markers alone or together with natriuretic peptide testing for diagnosis and short-term prognosis estimation in subjects with acute HF.Plasma levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP), apelin, and galectin-3 were measured in 599 patients presenting with dyspnea at the emergency department, of which 209 (35%) had acute HF.METHODSPlasma levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP), apelin, and galectin-3 were measured in 599 patients presenting with dyspnea at the emergency department, of which 209 (35%) had acute HF.The NT-proBNP was superior to either apelin or galectin-3 for diagnosis of acute HF, although galectin-3 levels were significantly higher in subjects with HF compared with those without. Receiver operating characteristic analysis for mortality prediction showed that, for 60-day prognosis, galectin-3 had the greatest area under the curve (AUC) at 0.74 (p = 0.0001), whereas NT-proBNP and apelin had an AUC of 0.67 (p = 0.009) and 0.54 (p = 0.33). In a multivariate logistic regression analysis, an elevated level of galectin-3 was the best independent predictor of 60-day mortality (odds ratio 10.3, p < 0.01) or the combination of death/recurrent HF within 60 days (odds ratio 14.3, p < 0.001). The Kaplan-Meier analyses showed that the combination of an elevated galectin-3 with NT-proBNP was a better predictor of mortality than either of the 2 markers alone.RESULTSThe NT-proBNP was superior to either apelin or galectin-3 for diagnosis of acute HF, although galectin-3 levels were significantly higher in subjects with HF compared with those without. Receiver operating characteristic analysis for mortality prediction showed that, for 60-day prognosis, galectin-3 had the greatest area under the curve (AUC) at 0.74 (p = 0.0001), whereas NT-proBNP and apelin had an AUC of 0.67 (p = 0.009) and 0.54 (p = 0.33). In a multivariate logistic regression analysis, an elevated level of galectin-3 was the best independent predictor of 60-day mortality (odds ratio 10.3, p < 0.01) or the combination of death/recurrent HF within 60 days (odds ratio 14.3, p < 0.001). The Kaplan-Meier analyses showed that the combination of an elevated galectin-3 with NT-proBNP was a better predictor of mortality than either of the 2 markers alone.Our data show potential utility of galectin-3 as a useful marker for evaluation of patients with suspected or proven acute HF, whereas apelin measurement was not useful for these indications. Moreover, the combination of galectin-3 with NT-proBNP was the best predictor for prognosis in subjects with acute HF.CONCLUSIONSOur data show potential utility of galectin-3 as a useful marker for evaluation of patients with suspected or proven acute HF, whereas apelin measurement was not useful for these indications. Moreover, the combination of galectin-3 with NT-proBNP was the best predictor for prognosis in subjects with acute HF. |
| Author | MacRae, Calum A. Low, Adrian F. Bakker, Jaap A. Martinez, Abelardo van Kimmenade, Roland R. Sharma, Umesh C. Ellinor, Patrick T. Januzzi, James L. Crijns, Harry J. Pinto, Yigal M. Menheere, Paul P. |
| Author_xml | – sequence: 1 givenname: Roland R. surname: van Kimmenade fullname: van Kimmenade, Roland R. organization: Department of Cardiology, University Hospital Maastricht, Maastricht, the Netherlands – sequence: 2 givenname: James L. surname: Januzzi fullname: Januzzi, James L. organization: Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts – sequence: 3 givenname: Patrick T. surname: Ellinor fullname: Ellinor, Patrick T. organization: Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts – sequence: 4 givenname: Umesh C. surname: Sharma fullname: Sharma, Umesh C. organization: Department of Cardiology, University Hospital Maastricht, Maastricht, the Netherlands – sequence: 5 givenname: Jaap A. surname: Bakker fullname: Bakker, Jaap A. organization: Department of Clinical Chemistry, University Hospital Maastricht, Maastricht, the Netherlands – sequence: 6 givenname: Adrian F. surname: Low fullname: Low, Adrian F. organization: Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts – sequence: 7 givenname: Abelardo surname: Martinez fullname: Martinez, Abelardo organization: Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts – sequence: 8 givenname: Harry J. surname: Crijns fullname: Crijns, Harry J. organization: Department of Cardiology, University Hospital Maastricht, Maastricht, the Netherlands – sequence: 9 givenname: Calum A. surname: MacRae fullname: MacRae, Calum A. organization: Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts – sequence: 10 givenname: Paul P. surname: Menheere fullname: Menheere, Paul P. organization: Department of Clinical Chemistry, University Hospital Maastricht, Maastricht, the Netherlands – sequence: 11 givenname: Yigal M. surname: Pinto fullname: Pinto, Yigal M. email: y.pinto@cardio.azm.nl organization: Department of Cardiology, University Hospital Maastricht, Maastricht, the Netherlands |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18123797$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16979009$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkl2LEzEYhQdZcT_0D3ghAdGrnZpMdvIhItRlP4RFC1a8DGnmDZuaTmqSWegv8G-bsdWFgutVcvGck7znvMfVQR96qKrnBE8IJuzNcrLUxkwajNkE0wlm5FF1RNpW1LSV_KA6wpy2NcGSH1bHKS1xAQWRT6pDwiSXGMuj6ufX7LzLGxQsmq5cH-o5xHJqj2Yx1B-idj36pHN0Q4TsDJrBOrsOTtGV9mCy62t6inTfoekafGFtiCjfArq4037Q2YV-tJ6VG_Q5oW8u36KpGTKga9Axo0vtfLF-Wj222id4tjtPqvnlxfz8ur75fPXxfHpTm7aluTaCCQn4rMNMWk2lXoCk1rJGGMu51sw0mAtuCbFtKxe0MQIkY4y2VkrS0ZPq9dZ2HcOPAVJWK5cMeK97CENSTAhG2VlTwJd74DIMscSSFGlL0rwlUhTqxY4aFivo1Dq6lY4b9SffArzaAToZ7W3UvXHpnhOkoVzywoktZ2JIKYJVxuXf6eXSgFcEq7FytVRj5WqsXGGqykeKtNmT_nV_SPRuK4KS9Z2DqJIpBRnoXCytqi64h-Xv9-SmdO_KhN9hA-k-KpUahdWXcRHHPcSsGHI2zvv23wb_e_0Xg7zrZw |
| CODEN | JACCDI |
| CitedBy_id | crossref_primary_10_1093_eurjhf_hfp035 crossref_primary_10_2174_1573403X15666191206163846 crossref_primary_10_1016_j_hfc_2011_11_005 crossref_primary_10_1016_j_acvd_2013_06_054 crossref_primary_10_1016_j_ijcard_2016_07_263 crossref_primary_10_3350_cmh_2021_0141 crossref_primary_10_1016_j_semerg_2022_101812 crossref_primary_10_1016_j_atherosclerosis_2014_09_014 crossref_primary_10_1007_s11897_017_0358_4 crossref_primary_10_1371_journal_pone_0271899 crossref_primary_10_1007_s40138_014_0042_x crossref_primary_10_1097_MBP_0000000000000197 crossref_primary_10_31083_j_rcm2411310 crossref_primary_10_1007_s11897_014_0207_7 crossref_primary_10_1097_MCI_0b013e328303e648 crossref_primary_10_1111_apt_16305 crossref_primary_10_3109_1354750X_2012_719037 crossref_primary_10_1093_eurjhf_hfp043 crossref_primary_10_1111_j_1749_6632_2011_06386_x crossref_primary_10_1161_HYPERTENSIONAHA_115_06032 crossref_primary_10_1186_s12967_021_02735_3 crossref_primary_10_1016_j_hfc_2021_01_002 crossref_primary_10_1093_eurheartj_ehs077 crossref_primary_10_33590_emjcardiol_20_00045 crossref_primary_10_3389_fcvm_2021_765081 crossref_primary_10_1016_j_clinbiochem_2010_02_001 crossref_primary_10_3390_ijms19123719 crossref_primary_10_1093_eurjhf_hfp179 crossref_primary_10_1093_eurjhf_hfs205 crossref_primary_10_1155_2016_7402784 crossref_primary_10_1016_j_arcmed_2016_12_009 crossref_primary_10_1016_j_ijcard_2016_01_179 crossref_primary_10_1016_S0300_8932_10_70155_X crossref_primary_10_3724_SP_J_1263_2012_02291 crossref_primary_10_1016_j_ahj_2014_02_011 crossref_primary_10_1038_nrg2983 crossref_primary_10_1016_j_ijcard_2014_03_016 crossref_primary_10_1007_s40138_013_0009_3 crossref_primary_10_1155_2018_2958219 crossref_primary_10_1016_j_regpep_2006_12_004 crossref_primary_10_1038_clpt_2013_139 crossref_primary_10_3109_1354750X_2015_1068856 crossref_primary_10_1136_heartjnl_2015_308975 crossref_primary_10_33678_cor_2011_127 crossref_primary_10_1002_ehf2_14151 crossref_primary_10_1373_clinchem_2016_259564 crossref_primary_10_1080_00015385_2021_1968155 crossref_primary_10_1016_j_ijcard_2016_08_070 crossref_primary_10_2174_0929867324666170830100424 crossref_primary_10_1016_j_tcm_2016_07_005 crossref_primary_10_1093_europace_euv045 crossref_primary_10_3390_biom11081167 crossref_primary_10_1186_s12872_016_0298_z crossref_primary_10_1016_j_hlc_2015_08_021 crossref_primary_10_2459_JCM_0b013e328361d1ef crossref_primary_10_1016_j_jacc_2021_12_012 crossref_primary_10_1002_rcm_4412 crossref_primary_10_1016_j_sleep_2021_03_039 crossref_primary_10_1016_j_hlc_2016_11_007 crossref_primary_10_1007_s10741_014_9447_6 crossref_primary_10_1155_2014_983098 crossref_primary_10_1161_JAHA_117_008371 crossref_primary_10_3343_alm_2018_38_4_306 crossref_primary_10_1177_1753944715578405 crossref_primary_10_1016_j_ijcard_2015_07_063 crossref_primary_10_14336_AD_2020_0604 crossref_primary_10_1016_j_jacc_2019_01_074 crossref_primary_10_1016_j_ejmech_2023_115542 crossref_primary_10_3390_biom10091277 crossref_primary_10_1016_j_ajpath_2015_12_017 crossref_primary_10_1016_j_ijcard_2016_09_079 crossref_primary_10_3390_ijms18050947 crossref_primary_10_1016_j_healun_2008_02_018 crossref_primary_10_1161_CIRCHEARTFAILURE_111_963637 crossref_primary_10_1080_14737159_2023_2216386 crossref_primary_10_1016_S1885_5857_10_70137_7 crossref_primary_10_1177_2048004020957840 crossref_primary_10_1016_j_vph_2016_02_006 crossref_primary_10_1161_CIRCEP_119_007519 crossref_primary_10_1002_jcu_23559 crossref_primary_10_1155_2015_457167 crossref_primary_10_3389_fvets_2021_741210 crossref_primary_10_1111_j_1751_7133_2011_00244_x crossref_primary_10_2217_bmm_15_121 crossref_primary_10_4103_apc_apc_146_21 crossref_primary_10_1093_eurjhf_hfr151 crossref_primary_10_1016_j_cardfail_2021_05_025 crossref_primary_10_1093_eurjhf_hfp097 crossref_primary_10_3109_1354750X_2011_574234 crossref_primary_10_1016_j_ijcard_2016_07_241 crossref_primary_10_1016_j_jacc_2020_01_014 crossref_primary_10_1186_1471_2261_13_91 crossref_primary_10_1016_j_rce_2018_10_004 crossref_primary_10_4137_CMT_S18476 crossref_primary_10_1016_j_clinbiochem_2012_04_009 crossref_primary_10_3892_mmr_2017_6429 crossref_primary_10_1016_j_jchf_2014_12_009 crossref_primary_10_18632_aging_202610 crossref_primary_10_4070_kcj_2023_0046 crossref_primary_10_1038_nrcardio_2010_51 crossref_primary_10_1016_j_ijcard_2014_09_011 crossref_primary_10_1016_j_tcm_2009_10_001 crossref_primary_10_36628_ijhf_2020_0036 crossref_primary_10_3390_jcm13164627 crossref_primary_10_20514_2226_6704_2021_11_2_98_110 crossref_primary_10_1016_j_cca_2013_12_017 crossref_primary_10_1111_1440_1681_13048 crossref_primary_10_3390_biom10030389 crossref_primary_10_1002_jbt_22717 crossref_primary_10_1161_JAHA_116_003700 crossref_primary_10_1016_j_jacc_2020_01_020 crossref_primary_10_1097_HCO_0000000000000077 crossref_primary_10_31083_j_rcm2403086 crossref_primary_10_1016_j_kint_2016_04_028 crossref_primary_10_1161_HYPERTENSIONAHA_118_11874 crossref_primary_10_17816_clinpract48893 crossref_primary_10_2217_bmm_2017_0376 crossref_primary_10_1136_heartjnl_2017_312070 crossref_primary_10_2217_bmm_14_55 crossref_primary_10_1152_japplphysiol_00474_2010 crossref_primary_10_1016_j_hlc_2016_12_012 crossref_primary_10_1161_JAHA_114_000962 crossref_primary_10_1016_j_acvd_2015_07_003 crossref_primary_10_1016_j_ahj_2012_08_021 crossref_primary_10_3390_biom14111478 crossref_primary_10_1021_ac9022346 crossref_primary_10_1016_j_ijcard_2011_05_081 crossref_primary_10_1016_j_pcad_2011_03_003 crossref_primary_10_1053_j_ajkd_2018_03_025 crossref_primary_10_1155_2019_8636930 crossref_primary_10_1681_ASN_2012090909 crossref_primary_10_1007_s11033_021_06150_1 crossref_primary_10_1177_2048872616652309 crossref_primary_10_1161_STROKEAHA_117_019084 crossref_primary_10_1007_s10557_014_6520_2 crossref_primary_10_2174_0118715230273606231103075632 crossref_primary_10_36628_ijhf_2023_0009 crossref_primary_10_1016_j_rec_2015_02_009 crossref_primary_10_1097_MEJ_0000000000001053 crossref_primary_10_1161_ATVBAHA_114_304964 crossref_primary_10_1016_j_ijcard_2013_08_081 crossref_primary_10_1515_labmed_2012_0073 crossref_primary_10_1016_j_hjc_2018_08_007 crossref_primary_10_2217_bmm_14_33 crossref_primary_10_5301_GTND_2017_16573 crossref_primary_10_1002_ejhf_21 crossref_primary_10_1097_HPC_0000000000000012 crossref_primary_10_1161_CIR_0000000000000490 crossref_primary_10_2217_bmm_14_31 crossref_primary_10_1161_CIRCHEARTFAILURE_117_004867 crossref_primary_10_3899_jrheum_110755 crossref_primary_10_3390_ijms24065089 crossref_primary_10_2217_bmm_2020_0269 crossref_primary_10_1016_j_ctrsc_2015_08_002 crossref_primary_10_3390_jpm14090994 crossref_primary_10_1016_j_cardfail_2015_03_007 crossref_primary_10_1152_ajpheart_00935_2007 crossref_primary_10_1016_j_cca_2008_03_002 crossref_primary_10_1080_00015385_2017_1408890 crossref_primary_10_1186_s12967_024_05192_w crossref_primary_10_1016_j_ijcard_2013_12_129 crossref_primary_10_1007_s11897_024_00684_8 crossref_primary_10_1002_ehf2_13595 crossref_primary_10_1111_sji_12826 crossref_primary_10_26442_CS45118 crossref_primary_10_1002_jcp_27910 crossref_primary_10_26442_CS45359 crossref_primary_10_1007_s11897_013_0151_y crossref_primary_10_1039_D3AY00347G crossref_primary_10_3390_cells11030588 crossref_primary_10_1016_j_ijcard_2012_06_087 crossref_primary_10_1161_CIRCHEARTFAILURE_112_000129 crossref_primary_10_1161_JAHA_112_000760 crossref_primary_10_1111_jocs_15954 crossref_primary_10_1159_000450573 crossref_primary_10_1517_17530059_2013_814638 crossref_primary_10_1016_j_jacc_2013_09_005 crossref_primary_10_1536_ihj_14_267 crossref_primary_10_17116_labs2024130315 crossref_primary_10_1016_j_acvd_2014_10_002 crossref_primary_10_1016_j_jhepr_2023_100911 crossref_primary_10_1016_j_imlet_2011_08_004 crossref_primary_10_1016_j_ijcard_2018_04_025 crossref_primary_10_1007_s12265_013_9465_0 crossref_primary_10_1002_elan_202060323 crossref_primary_10_1002_jcla_21996 crossref_primary_10_1002_ehf2_13174 crossref_primary_10_4103_2045_8932_87299 crossref_primary_10_1007_s12265_013_9467_y crossref_primary_10_1016_j_cca_2020_07_040 crossref_primary_10_3389_fcvm_2022_861651 crossref_primary_10_1016_j_bbadis_2012_12_014 crossref_primary_10_2174_1573403X17666210909170415 crossref_primary_10_2217_fca_12_65 crossref_primary_10_1038_ijo_2014_37 crossref_primary_10_1080_1354750X_2017_1319421 crossref_primary_10_1161_CIRCHEARTFAILURE_112_000146 crossref_primary_10_1002_ehf2_13144 crossref_primary_10_1080_00015385_2019_1669847 crossref_primary_10_1016_j_rceng_2019_02_005 crossref_primary_10_1007_s00011_023_01845_6 crossref_primary_10_1016_j_clinbiochem_2014_01_032 crossref_primary_10_1016_j_biopha_2020_111066 crossref_primary_10_15420_cfr_2021_37 crossref_primary_10_3760_cmaj_issn_0366_6999_20130217 crossref_primary_10_1016_j_amjmed_2014_10_035 crossref_primary_10_1002_ehf2_13032 crossref_primary_10_1161_CIRCHEARTFAILURE_121_008510 crossref_primary_10_1038_nrcardio_2012_60 crossref_primary_10_1007_s10741_008_9123_9 crossref_primary_10_1016_j_athoracsur_2019_05_072 crossref_primary_10_1016_j_jchf_2014_10_009 crossref_primary_10_18087_cardio_2020_1_n882 crossref_primary_10_1373_clinchem_2010_146506 crossref_primary_10_1007_s10741_014_9442_y crossref_primary_10_1093_eurjhf_hft077 crossref_primary_10_1016_j_repc_2014_10_005 crossref_primary_10_2217_bmm_2018_0381 crossref_primary_10_1016_j_jacc_2012_05_032 crossref_primary_10_1161_JAHA_116_004360 crossref_primary_10_1186_s12917_022_03343_z crossref_primary_10_1016_j_amjcard_2011_03_056 crossref_primary_10_1016_j_amjcard_2015_03_055 crossref_primary_10_1016_j_recesp_2015_02_009 crossref_primary_10_1002_ejhf_273 crossref_primary_10_1016_j_athoracsur_2020_03_010 crossref_primary_10_1161_JAHA_112_004374 crossref_primary_10_15420_cfr_2024_32 crossref_primary_10_3390_jcm9092932 crossref_primary_10_1517_17460441_3_1_51 crossref_primary_10_1016_j_ppedcard_2010_11_009 crossref_primary_10_1517_17460441_2011_571251 crossref_primary_10_1002_lt_24768 crossref_primary_10_1016_j_clinbiochem_2012_09_014 crossref_primary_10_1007_s10741_018_9683_2 crossref_primary_10_3390_jcm10153313 crossref_primary_10_3389_fcvm_2023_1235178 crossref_primary_10_1373_clinchem_2015_246850 crossref_primary_10_1161_CIR_0000000000001063 crossref_primary_10_3390_diseases6040088 crossref_primary_10_1586_14779072_2013_832476 crossref_primary_10_1007_s11897_024_00677_7 crossref_primary_10_2217_fca_16_1 crossref_primary_10_1007_s10741_014_9440_0 crossref_primary_10_1007_s11897_018_0399_3 crossref_primary_10_1161_JAHA_114_000785 crossref_primary_10_3390_life14040513 crossref_primary_10_1097_MD_0000000000004014 crossref_primary_10_1016_j_ijcha_2021_100863 crossref_primary_10_1093_eurheartjsupp_suac083 crossref_primary_10_1007_s00108_019_0606_7 crossref_primary_10_1007_s11033_018_4384_4 crossref_primary_10_1097_HJH_0000000000000149 crossref_primary_10_1016_j_athoracsur_2018_06_052 crossref_primary_10_1007_s00059_015_4303_6 crossref_primary_10_1155_2020_7614327 crossref_primary_10_1007_s10741_013_9396_5 crossref_primary_10_1016_j_cca_2014_10_009 crossref_primary_10_1016_j_clinbiochem_2014_06_001 crossref_primary_10_1002_ehf2_14603 crossref_primary_10_1080_10408363_2018_1525335 crossref_primary_10_3390_jcm10132771 crossref_primary_10_1097_CRD_0000000000000224 crossref_primary_10_1016_j_ahj_2013_12_031 crossref_primary_10_1681_ASN_2014010093 crossref_primary_10_1111_jch_12757 crossref_primary_10_1016_j_mcpro_2022_100207 crossref_primary_10_1016_j_cca_2014_10_023 crossref_primary_10_1056_NEJMra0800239 crossref_primary_10_1007_s11033_022_08207_1 crossref_primary_10_1038_s41598_024_61480_x crossref_primary_10_1097_CM9_0000000000000149 crossref_primary_10_1177_0004563217714004 crossref_primary_10_3390_ijms151223878 crossref_primary_10_1007_s11886_010_0109_6 crossref_primary_10_21886_2219_8075_2024_15_4_38_48 crossref_primary_10_3390_ijms19020379 crossref_primary_10_1007_s12265_013_9472_1 crossref_primary_10_3390_children9050740 crossref_primary_10_1161_JAHA_115_003079 crossref_primary_10_3390_diagnostics12061366 crossref_primary_10_1016_j_hfc_2014_04_005 crossref_primary_10_1016_j_jacc_2024_07_022 crossref_primary_10_3390_ijms23105680 crossref_primary_10_3390_ijms241310511 crossref_primary_10_15420_cfr_2023_24 crossref_primary_10_1016_j_crvasa_2013_04_003 crossref_primary_10_1007_s40265_015_0498_3 crossref_primary_10_1536_ihj_14_304 crossref_primary_10_1177_1753944717727498 crossref_primary_10_18632_oncotarget_28182 crossref_primary_10_1016_j_cjca_2016_02_070 crossref_primary_10_1161_CIRCHEARTFAILURE_122_009526 crossref_primary_10_1016_j_jacc_2012_06_040 crossref_primary_10_1016_j_jacc_2012_05_005 crossref_primary_10_1007_s00246_016_1488_2 crossref_primary_10_1161_CIRCRESAHA_114_302819 crossref_primary_10_2217_17520363_1_1_37 crossref_primary_10_1586_14737159_2014_892421 crossref_primary_10_1007_s11897_010_0004_x crossref_primary_10_1016_j_cca_2014_10_046 crossref_primary_10_1152_physrev_00008_2011 crossref_primary_10_1373_clinchem_2011_174359 crossref_primary_10_1371_journal_pone_0210971 crossref_primary_10_1007_s00392_010_0125_y crossref_primary_10_1017_S1047951120000451 crossref_primary_10_1016_j_jacc_2018_09_077 crossref_primary_10_2217_bmm_09_42 crossref_primary_10_1016_j_cardfail_2013_05_012 crossref_primary_10_2217_fca_14_9 crossref_primary_10_3390_ph16070978 crossref_primary_10_1586_14737159_2014_882772 crossref_primary_10_1016_j_repce_2014_10_003 crossref_primary_10_1016_j_cpcardiol_2022_101509 crossref_primary_10_1007_s00392_012_0500_y crossref_primary_10_1007_s40256_019_00387_9 crossref_primary_10_2217_bmm_09_52 crossref_primary_10_1373_clinchem_2009_138586 crossref_primary_10_15825_1995_1191_2019_2_145_149 crossref_primary_10_1093_eurjpc_zwad281 crossref_primary_10_1007_s11897_017_0342_z crossref_primary_10_1093_ejcts_ezu539 crossref_primary_10_1186_s43044_022_00317_2 crossref_primary_10_3390_diagnostics11091577 crossref_primary_10_1111_bjh_16112 crossref_primary_10_1007_s11897_015_0268_2 crossref_primary_10_1515_jce_2017_0013 crossref_primary_10_1007_s00059_014_4169_z crossref_primary_10_7759_cureus_67432 crossref_primary_10_3389_fcvm_2020_617705 crossref_primary_10_1080_14737159_2019_1671188 crossref_primary_10_1007_s00246_018_1879_7 crossref_primary_10_1097_HCO_0b013e3282f43039 crossref_primary_10_1152_ajpheart_00747_2008 crossref_primary_10_1016_j_amjcard_2016_09_019 crossref_primary_10_1016_j_cardfail_2014_10_006 crossref_primary_10_1007_s00059_018_4702_6 crossref_primary_10_1109_RBME_2019_2905730 crossref_primary_10_1016_j_healun_2012_11_011 crossref_primary_10_1002_ehf2_12728 crossref_primary_10_1007_s11897_014_0226_4 crossref_primary_10_1016_j_clinbiochem_2015_05_003 crossref_primary_10_1042_CS20200479 crossref_primary_10_3109_07853890_2010_538080 crossref_primary_10_1371_journal_pone_0123574 crossref_primary_10_1093_eurheartj_suy025 crossref_primary_10_1111_j_1755_6686_2013_12025_x crossref_primary_10_1002_ejhf_786 crossref_primary_10_1093_eurheartj_suy021 crossref_primary_10_1007_s10741_019_09858_2 crossref_primary_10_1016_j_cardfail_2013_04_002 crossref_primary_10_1002_ejhf_443 crossref_primary_10_1016_j_jacc_2012_04_053 crossref_primary_10_1177_2047487314552797 crossref_primary_10_1007_s00726_020_02855_y crossref_primary_10_1007_s40620_024_02047_x crossref_primary_10_3390_cells12091218 crossref_primary_10_1007_BF03165767 crossref_primary_10_1007_s10741_023_10347_w crossref_primary_10_1161_CIRCHEARTFAILURE_112_971168 crossref_primary_10_2478_rrlm_2018_0001 crossref_primary_10_1161_CIRCRESAHA_118_312706 crossref_primary_10_1373_clinchem_2011_165720 crossref_primary_10_1007_s11897_013_0169_1 crossref_primary_10_1111_j_1365_2796_2011_02476_x crossref_primary_10_1177_03000605241254330 crossref_primary_10_1016_j_cca_2009_09_001 crossref_primary_10_1016_j_abb_2020_108405 crossref_primary_10_1016_j_ejheart_2008_06_002 crossref_primary_10_3389_fcvm_2022_868658 crossref_primary_10_1007_BF03256468 crossref_primary_10_3109_1354750X_2011_561498 crossref_primary_10_1042_CS20171142 crossref_primary_10_1007_s11897_011_0065_5 crossref_primary_10_1177_2047487313492069 crossref_primary_10_1016_j_jchf_2012_10_002 crossref_primary_10_1002_ejhf_203 crossref_primary_10_1007_s10741_009_9144_z crossref_primary_10_3390_biomedicines12040707 crossref_primary_10_3390_ijms22052299 crossref_primary_10_1016_j_cll_2013_11_009 crossref_primary_10_1111_nyas_14123 crossref_primary_10_1007_s00740_019_00299_z crossref_primary_10_1016_j_arcmed_2018_08_007 crossref_primary_10_1371_journal_pone_0119160 crossref_primary_10_1210_clinem_dgaa427 crossref_primary_10_1016_j_carpath_2014_12_001 crossref_primary_10_1002_ehf2_14813 crossref_primary_10_1038_srep40994 crossref_primary_10_1016_j_amjmed_2012_04_033 crossref_primary_10_1586_14779072_2014_923307 crossref_primary_10_3390_diagnostics13111922 crossref_primary_10_3390_jcdd10030114 crossref_primary_10_1038_s41598_017_15265_0 crossref_primary_10_1016_j_cca_2014_09_006 crossref_primary_10_1016_j_hfc_2009_04_004 crossref_primary_10_1111_ctr_14592 crossref_primary_10_1016_j_cca_2016_10_034 crossref_primary_10_1016_j_ijcard_2015_10_127 crossref_primary_10_3390_biom11020166 crossref_primary_10_1007_s11936_011_0150_9 crossref_primary_10_2174_0929867324666170727110241 crossref_primary_10_1016_j_hfc_2011_06_001 crossref_primary_10_1161_CIRCHEARTFAILURE_116_003804 crossref_primary_10_1016_j_ijcard_2022_06_039 crossref_primary_10_18087_cardio_2021_5_n1530 crossref_primary_10_1007_s11886_020_01288_z crossref_primary_10_1373_clinchem_2008_108159 crossref_primary_10_1016_j_hrthm_2014_07_007 crossref_primary_10_1016_S1261_694X_15_30003_1 crossref_primary_10_3390_jcm8040559 crossref_primary_10_1007_s10741_017_9651_2 crossref_primary_10_1097_MAT_0000000000002292 crossref_primary_10_1016_j_amjcard_2007_11_020 crossref_primary_10_1161_JAHA_119_012336 crossref_primary_10_18410_jebmh_2020_177 crossref_primary_10_1016_j_hfc_2017_08_009 crossref_primary_10_1016_j_cca_2016_04_007 crossref_primary_10_1161_CIRCRESAHA_121_319916 crossref_primary_10_1093_cvr_cvp327 crossref_primary_10_1016_j_hfc_2009_04_007 crossref_primary_10_1007_s00059_017_4538_5 crossref_primary_10_1016_j_cardfail_2022_09_017 crossref_primary_10_1136_jclinpath_2016_203631 crossref_primary_10_1016_j_ahj_2014_12_012 crossref_primary_10_1155_2015_690205 crossref_primary_10_1016_j_hfc_2009_04_011 crossref_primary_10_1002_ejhf_407 |
| Cites_doi | 10.1161/01.CIR.0000039105.49749.6F 10.1161/01.CIR.0000144310.04433.BE 10.1373/clinchem.2003.021311 10.1016/S0006-291X(03)01424-4 10.1056/NEJMoa020233 10.1016/S0002-9343(00)00743-9 10.1136/bmj.330.7492.625 10.1161/01.CIR.0000091235.94914.75 10.1161/01.CIR.0000047274.66749.FE 10.1067/mhl.2002.124554 10.1074/jbc.M404149200 10.1161/01.CIR.0000145158.33801.F3 10.1161/01.CIR.0000155614.35441.69 10.1001/jama.287.7.883 10.1038/nrc1527 10.1016/S0735-1097(00)00995-5 10.1161/01.CIR.97.12.1136 10.1253/circj.68.1160 10.1378/chest.105.3.897 10.1016/j.ehj.2004.06.038 10.1161/01.CIR.102.10.1126 10.1161/01.RES.0000033522.37861.69 10.1074/jbc.M908417199 10.1016/S0002-9149(01)02341-4 10.1161/01.CIR.0000147181.65298.4D 10.1016/S0735-1097(96)00268-9 10.1056/NEJMe030030 10.1161/01.HYP.38.3.588 10.1016/j.amjcard.2004.12.032 10.1016/S0735-1097(03)00761-7 10.1023/B:GLYC.0000014072.34840.04 10.1016/j.jacc.2004.12.029 10.1056/NEJMoa013474 10.1093/oxfordjournals.eurheartj.a015268 10.1016/S0304-4165(99)00177-4 10.1056/NEJMra021498 10.1161/01.CIR.93.4.704 10.1097/01.hco.0000161832.04952.6a 10.1016/S0304-4165(02)00310-0 10.1006/bbrc.1998.9489 |
| ContentType | Journal Article |
| Copyright | 2006 American College of Cardiology Foundation American College of Cardiology Foundation 2006 INIST-CNRS Copyright Elsevier Limited Sep 19, 2006 |
| Copyright_xml | – notice: 2006 American College of Cardiology Foundation – notice: American College of Cardiology Foundation – notice: 2006 INIST-CNRS – notice: Copyright Elsevier Limited Sep 19, 2006 |
| DBID | 6I. AAFTH AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7TK H94 K9. NAPCQ 7X8 |
| DOI | 10.1016/j.jacc.2006.03.061 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Neurosciences Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Immunology Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1558-3597 |
| EndPage | 1224 |
| ExternalDocumentID | 3242773201 16979009 18123797 10_1016_j_jacc_2006_03_061 S0735109706016767 1_s2_0_S0735109706016767 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL075431 |
| GroupedDBID | --- --K --M .GJ .~1 0R~ 18M 1B1 1~. 1~5 2WC 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ AABNK AAEDT AAEDW AAIKJ AAOAW AAQFI AAXUO ABBQC ABFNM ABFRF ABLJU ABMAC ABOCM ABWVN ABXDB ACGFO ACGFS ACIUM ACJTP ACPRK ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEFWE AEKER AENEX AEUPX AEXQZ AFFNX AFPUW AFRAH AFTJW AGCQF AGHFR AGYEJ AHMBA AIGII AITUG AJRQY AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BLXMC CS3 DIK DU5 E3Z EBS EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FNPLU G-Q GX1 H13 HVGLF HZ~ IHE IXB J1W J5H K-O KQ8 L7B MO0 N9A O-L O9- OAUVE OK1 OZT P-9 P2P PC. PQQKQ PROAC Q38 QTD ROL RPZ SCC SDF SDG SDP SES SSZ TR2 UNMZH UV1 W8F WH7 WOQ WOW YYM YYP YZZ .1- .55 .FO 0SF 1CY 1P~ 29L 3V. 6I. 7RV AABVL AACTN AAFTH AAKUH AALRI AAQQT AAQXK AAYOK ABMZM ABVKL AEVXI AFCTW AFETI AFRHN AJOXV AMFUW ASPBG AVWKF AZFZN BENPR BPHCQ FGOYB GBLVA HX~ N4W NCXOZ OA. OL~ P-8 R2- RIG SEW T5K X7M XPP Z5R ZGI ZXP AAIAV ABJNI EFLBG LCYCR NAHTW ZA5 AAYWO AAYXX AGQPQ CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7TK H94 K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c553t-c8689e04d069fa39abe93ff628cf77aa6c20787f11f559b32c8e966635f991d3 |
| IEDL.DBID | IXB |
| ISSN | 0735-1097 1558-3597 |
| IngestDate | Thu Aug 07 14:42:31 EDT 2025 Sat Jul 26 03:22:17 EDT 2025 Wed Feb 19 01:43:20 EST 2025 Mon Jul 21 09:16:34 EDT 2025 Tue Jul 01 03:46:35 EDT 2025 Thu Apr 24 23:05:17 EDT 2025 Fri Feb 23 02:16:42 EST 2024 Mon Feb 24 20:34:15 EST 2025 Tue Aug 26 18:45:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | NYHA gal NT-proBNP OR BNP PRIDE CI CAD ROC IQR HF AUC coronary artery disease heart failure brain natriuretic peptide area under the curve interquartile range odds ratio amino-terminal pro-brain natriuretic peptide New York Heart Association galectin N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department confidence interval receiver operating characteristic Galectin Human Heart failure Evaluation Brain natriuretic peptide Heart disease Acute Cardiovascular disease Circulatory system Cardiology Phlebology Aminoacid sequence |
| Language | English |
| License | http://www.elsevier.com/open-access/userlicense/1.0 https://www.elsevier.com/tdm/userlicense/1.0 https://www.elsevier.com/open-access/userlicense/1.0 CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c553t-c8689e04d069fa39abe93ff628cf77aa6c20787f11f559b32c8e966635f991d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0735109706016767 |
| PMID | 16979009 |
| PQID | 1506175198 |
| PQPubID | 2031078 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_68863642 proquest_journals_1506175198 pubmed_primary_16979009 pascalfrancis_primary_18123797 crossref_citationtrail_10_1016_j_jacc_2006_03_061 crossref_primary_10_1016_j_jacc_2006_03_061 elsevier_sciencedirect_doi_10_1016_j_jacc_2006_03_061 elsevier_clinicalkeyesjournals_1_s2_0_S0735109706016767 elsevier_clinicalkey_doi_10_1016_j_jacc_2006_03_061 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2006-09-19 |
| PublicationDateYYYYMMDD | 2006-09-19 |
| PublicationDate_xml | – month: 09 year: 2006 text: 2006-09-19 day: 19 |
| PublicationDecade | 2000 |
| PublicationPlace | New York, NY |
| PublicationPlace_xml | – name: New York, NY – name: United States – name: New York |
| PublicationTitle | Journal of the American College of Cardiology |
| PublicationTitleAlternate | J Am Coll Cardiol |
| PublicationYear | 2006 |
| Publisher | Elsevier Inc Elsevier Science Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Science – name: Elsevier Limited |
| References | MacIntyre, Capewell, Stewart (bib4) 2000; 102 Foldes, Horkay, Szokodi (bib40) 2003; 308 Taniguchi, Sato, Yamada (bib31) 2004; 68 Chen, Ashley, Deng (bib14) 2003; 108 Devaux, Scholz, Hirche, Klovekorn, Schaper (bib21) 1997; 18 Aukrust, Ueland, Muller (bib34) 1998; 97 Szokodi, Tavi, Foldes (bib36) 2002; 91 Jessup (bib15) 2003; 348 Ishida, Hashimoto, Hashimoto (bib39) 2004; 279 Bleumink, Knetsch, Sturkenboom (bib1) 2004; 25 Iurisci, Tinari, Natoli (bib28) 2000; 6 Valgimigli, Ceconi, Malagutti (bib33) 2005; 111 Perna, Macin, Canella (bib32) 2004; 110 Hughes (bib26) 1999; 1473 Tatemoto, Hosoya, Habata (bib37) 1998; 251 Maisel, Krishnaswamy, Nowak (bib7) 2002; 347 McMurray, Hillier (bib41) 2003; 42 Doust, Pietrzak, Dobson, Glasziou (bib10) 2005; 330 McAlister, Lawson, Teo, Armstrong (bib17) 2001; 110 Ishii, Cui, Kitagawa (bib29) 2003; 49 Testa, Yeh, Lee (bib20) 1996; 28 Ishii, Nomura, Nakamura (bib30) 2002; 89 Jessup, Brozena (bib3) 2003; 348 Leffler, Carlsson, Hedlund, Qian, Poirier (bib25) 2004; 19 Hosoya, Kawamata, Fukusumi (bib38) 2000; 275 Khand, Gemmel, Clark, Cleland (bib5) 2000; 36 Liu, Rabinovich (bib23) 2005; 5 Lloyd-Jones, Larson, Leip (bib2) 2002; 106 Bennett, Riegel, Bittner, Nichols (bib42) 2002; 31 Dolgin (bib43) 2005; 45 Moss, Zareba, Hall (bib18) 2002; 346 Lee, Vasan (bib6) 2005; 20 Torre-Amione, Kapadia, Lee (bib22) 1996; 93 Bruneau, Piazza, deBold (bib11) 1997; 273 Bettencourt, Azevedo, Pimenta (bib9) 2004; 110 Weinberg, Shimpo, Hurwitz (bib35) 2003; 107 Weber (bib19) 2001; 38 Foody, Farrell, Krumholz (bib16) 2002; 287 Sharma, Pokharel, vanBrakel (bib13) 2004; 110 Cooper (bib24) 2002; 1572 Mann, Young (bib12) 1994; 105 Nachtigal, Al-Assaad, Mayer, Kim, Monsigny (bib27) 1998; 152 Januzzi, Camargo, Anwaruddin (bib8) 2005; 95 Bettencourt (10.1016/j.jacc.2006.03.061_bib9) 2004; 110 Ishii (10.1016/j.jacc.2006.03.061_bib30) 2002; 89 Valgimigli (10.1016/j.jacc.2006.03.061_bib33) 2005; 111 Moss (10.1016/j.jacc.2006.03.061_bib18) 2002; 346 Perna (10.1016/j.jacc.2006.03.061_bib32) 2004; 110 Khand (10.1016/j.jacc.2006.03.061_bib5) 2000; 36 Devaux (10.1016/j.jacc.2006.03.061_bib21) 1997; 18 Bruneau (10.1016/j.jacc.2006.03.061_bib11) 1997; 273 Sharma (10.1016/j.jacc.2006.03.061_bib13) 2004; 110 Ishii (10.1016/j.jacc.2006.03.061_bib29) 2003; 49 Foldes (10.1016/j.jacc.2006.03.061_bib40) 2003; 308 Foody (10.1016/j.jacc.2006.03.061_bib16) 2002; 287 Iurisci (10.1016/j.jacc.2006.03.061_bib28) 2000; 6 Taniguchi (10.1016/j.jacc.2006.03.061_bib31) 2004; 68 Lloyd-Jones (10.1016/j.jacc.2006.03.061_bib2) 2002; 106 Aukrust (10.1016/j.jacc.2006.03.061_bib34) 1998; 97 Lee (10.1016/j.jacc.2006.03.061_bib6) 2005; 20 Hughes (10.1016/j.jacc.2006.03.061_bib26) 1999; 1473 Tatemoto (10.1016/j.jacc.2006.03.061_bib37) 1998; 251 MacIntyre (10.1016/j.jacc.2006.03.061_bib4) 2000; 102 Weber (10.1016/j.jacc.2006.03.061_bib19) 2001; 38 Jessup (10.1016/j.jacc.2006.03.061_bib15) 2003; 348 Cooper (10.1016/j.jacc.2006.03.061_bib24) 2002; 1572 Hosoya (10.1016/j.jacc.2006.03.061_bib38) 2000; 275 Mann (10.1016/j.jacc.2006.03.061_bib12) 1994; 105 Leffler (10.1016/j.jacc.2006.03.061_bib25) 2004; 19 Ishida (10.1016/j.jacc.2006.03.061_bib39) 2004; 279 Nachtigal (10.1016/j.jacc.2006.03.061_bib27) 1998; 152 Chen (10.1016/j.jacc.2006.03.061_bib14) 2003; 108 Szokodi (10.1016/j.jacc.2006.03.061_bib36) 2002; 91 Doust (10.1016/j.jacc.2006.03.061_bib10) 2005; 330 Bennett (10.1016/j.jacc.2006.03.061_bib42) 2002; 31 Dolgin (10.1016/j.jacc.2006.03.061_bib43) 2005; 45 Maisel (10.1016/j.jacc.2006.03.061_bib7) 2002; 347 McAlister (10.1016/j.jacc.2006.03.061_bib17) 2001; 110 Bleumink (10.1016/j.jacc.2006.03.061_bib1) 2004; 25 Torre-Amione (10.1016/j.jacc.2006.03.061_bib22) 1996; 93 Januzzi (10.1016/j.jacc.2006.03.061_bib8) 2005; 95 Weinberg (10.1016/j.jacc.2006.03.061_bib35) 2003; 107 Jessup (10.1016/j.jacc.2006.03.061_bib3) 2003; 348 Testa (10.1016/j.jacc.2006.03.061_bib20) 1996; 28 Liu (10.1016/j.jacc.2006.03.061_bib23) 2005; 5 McMurray (10.1016/j.jacc.2006.03.061_bib41) 2003; 42 |
| References_xml | – volume: 102 start-page: 1126 year: 2000 end-page: 1131 ident: bib4 article-title: Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995 publication-title: Circulation – volume: 19 start-page: 433 year: 2004 end-page: 440 ident: bib25 article-title: Introduction to galectins publication-title: Glycoconj J – volume: 20 start-page: 201 year: 2005 end-page: 210 ident: bib6 article-title: Novel markers for heart failure diagnosis and prognosis publication-title: Curr Opin Cardiol – volume: 45 start-page: 967 year: 2005 ident: bib43 article-title: Obesity and B-type natriuretic peptide levels in heart failure publication-title: J Am Coll Cardiol – volume: 25 start-page: 1614 year: 2004 end-page: 1619 ident: bib1 article-title: Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study publication-title: Eur Heart J – volume: 251 start-page: 471 year: 1998 end-page: 476 ident: bib37 article-title: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor publication-title: Biochem Biophys Res Commun – volume: 108 start-page: 1432 year: 2003 end-page: 1439 ident: bib14 article-title: Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction publication-title: Circulation – volume: 18 start-page: 470 year: 1997 end-page: 479 ident: bib21 article-title: Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure publication-title: Eur Heart J – volume: 97 start-page: 1136 year: 1998 end-page: 1143 ident: bib34 article-title: Elevated circulating levels of C-C chemokines in patients with congestive heart failure publication-title: Circulation – volume: 273 start-page: H2678 year: 1997 end-page: H2686 ident: bib11 article-title: BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria publication-title: Am J Physiol – volume: 110 start-page: 3121 year: 2004 end-page: 3128 ident: bib13 article-title: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction publication-title: Circulation – volume: 1572 start-page: 209 year: 2002 end-page: 231 ident: bib24 article-title: Galectinomics: finding themes in complexity publication-title: Biochim Biophys Acta – volume: 330 start-page: 625 year: 2005 ident: bib10 article-title: How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review publication-title: BMJ – volume: 89 start-page: 691 year: 2002 end-page: 695 ident: bib30 article-title: Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure publication-title: Am J Cardiol – volume: 42 start-page: 726 year: 2003 end-page: 727 ident: bib41 article-title: The rise and fall of myotrophin in heart failure publication-title: J Am Coll Cardiol – volume: 347 start-page: 161 year: 2002 end-page: 167 ident: bib7 article-title: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure publication-title: N Engl J Med – volume: 31 start-page: 262 year: 2002 end-page: 270 ident: bib42 article-title: Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease publication-title: Heart Lung – volume: 110 start-page: 2168 year: 2004 end-page: 2174 ident: bib9 article-title: N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients publication-title: Circulation – volume: 110 start-page: 378 year: 2001 end-page: 384 ident: bib17 article-title: A systematic review of randomized trials of disease management programs in heart failure publication-title: Am J Med – volume: 5 start-page: 29 year: 2005 end-page: 41 ident: bib23 article-title: Galectins as modulators of tumour progression publication-title: Nat Rev Cancer – volume: 91 start-page: 434 year: 2002 end-page: 440 ident: bib36 article-title: Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility publication-title: Circ Res – volume: 308 start-page: 480 year: 2003 end-page: 485 ident: bib40 article-title: Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure publication-title: Biochem Biophys Res Commun – volume: 1473 start-page: 172 year: 1999 end-page: 185 ident: bib26 article-title: Secretion of the galectin family of mammalian carbohydrate-binding proteins publication-title: Biochim Biophys Acta – volume: 105 start-page: 897 year: 1994 end-page: 904 ident: bib12 article-title: Basic mechanisms in congestive heart failure publication-title: Chest – volume: 95 start-page: 948 year: 2005 end-page: 954 ident: bib8 article-title: The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study publication-title: Am J Cardiol – volume: 93 start-page: 704 year: 1996 end-page: 711 ident: bib22 article-title: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart publication-title: Circulation – volume: 111 start-page: 863 year: 2005 end-page: 870 ident: bib33 article-title: Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study publication-title: Circulation – volume: 106 start-page: 3068 year: 2002 end-page: 3072 ident: bib2 article-title: Lifetime risk for developing congestive heart failure: the Framingham Heart Study publication-title: Circulation – volume: 38 start-page: 588 year: 2001 end-page: 591 ident: bib19 article-title: Cardioreparation in hypertensive heart disease publication-title: Hypertension – volume: 107 start-page: 721 year: 2003 end-page: 726 ident: bib35 article-title: Identification of serum soluble ST2 receptor as a novel heart failure biomarker publication-title: Circulation – volume: 68 start-page: 1160 year: 2004 end-page: 1164 ident: bib31 article-title: Combined measurements of cardiac troponin T and N-terminal pro-brain natriuretic peptide in patients with heart failure publication-title: Circ J – volume: 36 start-page: 2284 year: 2000 end-page: 2286 ident: bib5 article-title: Is the prognosis of heart failure improving? publication-title: J Am Coll Cardiol – volume: 348 start-page: 1380 year: 2003 end-page: 1382 ident: bib15 article-title: Aldosterone blockade and heart failure publication-title: N Engl J Med – volume: 152 start-page: 1199 year: 1998 end-page: 1208 ident: bib27 article-title: Galectin-3 expression in human atherosclerotic lesions publication-title: Am J Pathol – volume: 6 start-page: 1389 year: 2000 end-page: 1393 ident: bib28 article-title: Concentrations of galectin-3 in the sera of normal controls and cancer patients publication-title: Clin Cancer Res – volume: 346 start-page: 877 year: 2002 end-page: 883 ident: bib18 article-title: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction publication-title: N Engl J Med – volume: 49 start-page: 2020 year: 2003 end-page: 2026 ident: bib29 article-title: Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure publication-title: Clin Chem – volume: 287 start-page: 883 year: 2002 end-page: 889 ident: bib16 article-title: Beta-blocker therapy in heart failure: scientific review publication-title: JAMA – volume: 28 start-page: 964 year: 1996 end-page: 971 ident: bib20 article-title: Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension publication-title: J Am Coll Cardiol – volume: 275 start-page: 21061 year: 2000 end-page: 21067 ident: bib38 article-title: Molecular and functional characteristics of APJ publication-title: J Biol Chem – volume: 110 start-page: 2376 year: 2004 end-page: 2382 ident: bib32 article-title: Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification publication-title: Circulation – volume: 348 start-page: 2007 year: 2003 end-page: 2018 ident: bib3 article-title: Heart failure publication-title: N Engl J Med – volume: 279 start-page: 26274 year: 2004 end-page: 26279 ident: bib39 article-title: Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo publication-title: J Biol Chem – volume: 106 start-page: 3068 year: 2002 ident: 10.1016/j.jacc.2006.03.061_bib2 article-title: Lifetime risk for developing congestive heart failure: the Framingham Heart Study publication-title: Circulation doi: 10.1161/01.CIR.0000039105.49749.6F – volume: 110 start-page: 2168 year: 2004 ident: 10.1016/j.jacc.2006.03.061_bib9 article-title: N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients publication-title: Circulation doi: 10.1161/01.CIR.0000144310.04433.BE – volume: 49 start-page: 2020 year: 2003 ident: 10.1016/j.jacc.2006.03.061_bib29 article-title: Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure publication-title: Clin Chem doi: 10.1373/clinchem.2003.021311 – volume: 308 start-page: 480 year: 2003 ident: 10.1016/j.jacc.2006.03.061_bib40 article-title: Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure publication-title: Biochem Biophys Res Commun doi: 10.1016/S0006-291X(03)01424-4 – volume: 6 start-page: 1389 year: 2000 ident: 10.1016/j.jacc.2006.03.061_bib28 article-title: Concentrations of galectin-3 in the sera of normal controls and cancer patients publication-title: Clin Cancer Res – volume: 152 start-page: 1199 year: 1998 ident: 10.1016/j.jacc.2006.03.061_bib27 article-title: Galectin-3 expression in human atherosclerotic lesions publication-title: Am J Pathol – volume: 347 start-page: 161 year: 2002 ident: 10.1016/j.jacc.2006.03.061_bib7 article-title: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure publication-title: N Engl J Med doi: 10.1056/NEJMoa020233 – volume: 110 start-page: 378 year: 2001 ident: 10.1016/j.jacc.2006.03.061_bib17 article-title: A systematic review of randomized trials of disease management programs in heart failure publication-title: Am J Med doi: 10.1016/S0002-9343(00)00743-9 – volume: 330 start-page: 625 year: 2005 ident: 10.1016/j.jacc.2006.03.061_bib10 article-title: How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review publication-title: BMJ doi: 10.1136/bmj.330.7492.625 – volume: 108 start-page: 1432 year: 2003 ident: 10.1016/j.jacc.2006.03.061_bib14 article-title: Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction publication-title: Circulation doi: 10.1161/01.CIR.0000091235.94914.75 – volume: 107 start-page: 721 year: 2003 ident: 10.1016/j.jacc.2006.03.061_bib35 article-title: Identification of serum soluble ST2 receptor as a novel heart failure biomarker publication-title: Circulation doi: 10.1161/01.CIR.0000047274.66749.FE – volume: 31 start-page: 262 year: 2002 ident: 10.1016/j.jacc.2006.03.061_bib42 article-title: Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease publication-title: Heart Lung doi: 10.1067/mhl.2002.124554 – volume: 279 start-page: 26274 year: 2004 ident: 10.1016/j.jacc.2006.03.061_bib39 article-title: Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo publication-title: J Biol Chem doi: 10.1074/jbc.M404149200 – volume: 110 start-page: 2376 year: 2004 ident: 10.1016/j.jacc.2006.03.061_bib32 article-title: Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification publication-title: Circulation doi: 10.1161/01.CIR.0000145158.33801.F3 – volume: 111 start-page: 863 year: 2005 ident: 10.1016/j.jacc.2006.03.061_bib33 article-title: Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study publication-title: Circulation doi: 10.1161/01.CIR.0000155614.35441.69 – volume: 287 start-page: 883 year: 2002 ident: 10.1016/j.jacc.2006.03.061_bib16 article-title: Beta-blocker therapy in heart failure: scientific review publication-title: JAMA doi: 10.1001/jama.287.7.883 – volume: 5 start-page: 29 year: 2005 ident: 10.1016/j.jacc.2006.03.061_bib23 article-title: Galectins as modulators of tumour progression publication-title: Nat Rev Cancer doi: 10.1038/nrc1527 – volume: 36 start-page: 2284 year: 2000 ident: 10.1016/j.jacc.2006.03.061_bib5 article-title: Is the prognosis of heart failure improving? publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(00)00995-5 – volume: 97 start-page: 1136 year: 1998 ident: 10.1016/j.jacc.2006.03.061_bib34 article-title: Elevated circulating levels of C-C chemokines in patients with congestive heart failure publication-title: Circulation doi: 10.1161/01.CIR.97.12.1136 – volume: 68 start-page: 1160 year: 2004 ident: 10.1016/j.jacc.2006.03.061_bib31 article-title: Combined measurements of cardiac troponin T and N-terminal pro-brain natriuretic peptide in patients with heart failure publication-title: Circ J doi: 10.1253/circj.68.1160 – volume: 105 start-page: 897 year: 1994 ident: 10.1016/j.jacc.2006.03.061_bib12 article-title: Basic mechanisms in congestive heart failure publication-title: Chest doi: 10.1378/chest.105.3.897 – volume: 25 start-page: 1614 year: 2004 ident: 10.1016/j.jacc.2006.03.061_bib1 article-title: Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study publication-title: Eur Heart J doi: 10.1016/j.ehj.2004.06.038 – volume: 102 start-page: 1126 year: 2000 ident: 10.1016/j.jacc.2006.03.061_bib4 article-title: Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995 publication-title: Circulation doi: 10.1161/01.CIR.102.10.1126 – volume: 91 start-page: 434 year: 2002 ident: 10.1016/j.jacc.2006.03.061_bib36 article-title: Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility publication-title: Circ Res doi: 10.1161/01.RES.0000033522.37861.69 – volume: 275 start-page: 21061 year: 2000 ident: 10.1016/j.jacc.2006.03.061_bib38 article-title: Molecular and functional characteristics of APJ publication-title: J Biol Chem doi: 10.1074/jbc.M908417199 – volume: 89 start-page: 691 year: 2002 ident: 10.1016/j.jacc.2006.03.061_bib30 article-title: Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure publication-title: Am J Cardiol doi: 10.1016/S0002-9149(01)02341-4 – volume: 110 start-page: 3121 year: 2004 ident: 10.1016/j.jacc.2006.03.061_bib13 article-title: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction publication-title: Circulation doi: 10.1161/01.CIR.0000147181.65298.4D – volume: 28 start-page: 964 year: 1996 ident: 10.1016/j.jacc.2006.03.061_bib20 article-title: Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(96)00268-9 – volume: 348 start-page: 1380 year: 2003 ident: 10.1016/j.jacc.2006.03.061_bib15 article-title: Aldosterone blockade and heart failure publication-title: N Engl J Med doi: 10.1056/NEJMe030030 – volume: 38 start-page: 588 year: 2001 ident: 10.1016/j.jacc.2006.03.061_bib19 article-title: Cardioreparation in hypertensive heart disease publication-title: Hypertension doi: 10.1161/01.HYP.38.3.588 – volume: 95 start-page: 948 year: 2005 ident: 10.1016/j.jacc.2006.03.061_bib8 article-title: The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2004.12.032 – volume: 42 start-page: 726 year: 2003 ident: 10.1016/j.jacc.2006.03.061_bib41 article-title: The rise and fall of myotrophin in heart failure publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(03)00761-7 – volume: 273 start-page: H2678 year: 1997 ident: 10.1016/j.jacc.2006.03.061_bib11 article-title: BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria publication-title: Am J Physiol – volume: 19 start-page: 433 year: 2004 ident: 10.1016/j.jacc.2006.03.061_bib25 article-title: Introduction to galectins publication-title: Glycoconj J doi: 10.1023/B:GLYC.0000014072.34840.04 – volume: 45 start-page: 967 year: 2005 ident: 10.1016/j.jacc.2006.03.061_bib43 article-title: Obesity and B-type natriuretic peptide levels in heart failure publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2004.12.029 – volume: 346 start-page: 877 year: 2002 ident: 10.1016/j.jacc.2006.03.061_bib18 article-title: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction publication-title: N Engl J Med doi: 10.1056/NEJMoa013474 – volume: 18 start-page: 470 year: 1997 ident: 10.1016/j.jacc.2006.03.061_bib21 article-title: Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure publication-title: Eur Heart J doi: 10.1093/oxfordjournals.eurheartj.a015268 – volume: 1473 start-page: 172 year: 1999 ident: 10.1016/j.jacc.2006.03.061_bib26 article-title: Secretion of the galectin family of mammalian carbohydrate-binding proteins publication-title: Biochim Biophys Acta doi: 10.1016/S0304-4165(99)00177-4 – volume: 348 start-page: 2007 year: 2003 ident: 10.1016/j.jacc.2006.03.061_bib3 article-title: Heart failure publication-title: N Engl J Med doi: 10.1056/NEJMra021498 – volume: 93 start-page: 704 year: 1996 ident: 10.1016/j.jacc.2006.03.061_bib22 article-title: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart publication-title: Circulation doi: 10.1161/01.CIR.93.4.704 – volume: 20 start-page: 201 year: 2005 ident: 10.1016/j.jacc.2006.03.061_bib6 article-title: Novel markers for heart failure diagnosis and prognosis publication-title: Curr Opin Cardiol doi: 10.1097/01.hco.0000161832.04952.6a – volume: 1572 start-page: 209 year: 2002 ident: 10.1016/j.jacc.2006.03.061_bib24 article-title: Galectinomics: finding themes in complexity publication-title: Biochim Biophys Acta doi: 10.1016/S0304-4165(02)00310-0 – volume: 251 start-page: 471 year: 1998 ident: 10.1016/j.jacc.2006.03.061_bib37 article-title: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1998.9489 |
| SSID | ssj0006819 |
| Score | 2.4285705 |
| Snippet | Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure
Roland R. van... Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure Roland R. van... This study sought to explore the role of new biomarkers in heart failure (HF). We investigated the utility of novel serum markers alone or together with... This study sought to explore the role of new biomarkers in heart failure (HF).OBJECTIVESThis study sought to explore the role of new biomarkers in heart... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1217 |
| SubjectTerms | Acute Disease Age Aged Aged, 80 and over Apelin Biological and medical sciences Biomarkers - blood Cardiology Cardiology. Vascular system Cardiomyopathy Cardiovascular Cardiovascular disease Classification Confidence intervals Diabetes Dyspnea - blood Enzymes Family medical history Female Galectin 3 - blood Heart Heart attacks Heart failure Heart Failure - blood Heart Failure - diagnosis Heart Failure - mortality Heart failure, cardiogenic pulmonary edema, cardiac enlargement Humans Hypertension Intercellular Signaling Peptides and Proteins - blood Male Medical prognosis Medical sciences Middle Aged Mortality Multivariate analysis Natriuretic Peptide, Brain - blood Osmolar Concentration Peptide Fragments - blood Peptides Prognosis Rodents Survival Analysis Time Factors |
| Title | Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0735109706016767 https://www.clinicalkey.es/playcontent/1-s2.0-S0735109706016767 https://dx.doi.org/10.1016/j.jacc.2006.03.061 https://www.ncbi.nlm.nih.gov/pubmed/16979009 https://www.proquest.com/docview/1506175198 https://www.proquest.com/docview/68863642 |
| Volume | 48 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKDwgJId4EyuIDN-puEid-HLdVlxVSq5XYir1ZjmOrqUqyarIHLlz524zzWlXQInFNbMfxjGc-e14IfeQmFJnIOckBK5DEWU4yruHgqkMpbJzJhPoA57NztrhIvqzT9R46GWJhvFtlL_s7md5K6_7JtF_N6aYopl-BOVNvP20zinDmI8ppItogvvXxKI2ZaIt7-MbEt-4DZzofryttTG-QoEchi-5STo83uoYlc12ti7vBaKuU5k_Rkx5N4lk34Wdoz5bP0cOz3l7-Av26aLzv6w9cOTz7XpQVWXXOL9d4eVORY18fAp_7LP3bNpoRL72TS24P8Wft7_OLktBDrMsczzY-cB0DxMUAGfHpmCTcD73skrPW-FvRXOKZ2TYWL2ALNXiuC-_3_hKt5qerkwXpSy8Qk6a0IUYwIW2Y5CGTTlOpMyupcywWxnGuNTMxYAvuosjBkSSjsREWDk6AXhwAzpy-QvtlVdo3CEtBHVA8d2mkve7TkcmyVOZAqTSXoQ5QNCy5Mn1acl8d41oN_mdXypPJ18tkKqQKyBSgT2OfTZeU497WdKCkGsJNQUAq0Bn39uJ_62Xrfo_XKlJ1rEL1Bx8GKB173mLlf35xcovNdr8GIIxyCQMfDHyndrNIPQgFHC4C9GF8DTLCG350aattrZgQjMJBM0CvO27dDc0klwCz3_7nnN-hR92dlCSRPED7zc3WvgeU1mQT9ODoZzRpN-NvoZI5LA |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Lb9MwGLfGkABpQrzGCmPzgRvzmsSJH8cyrRRYq0p0YjfLcWyRaSTVkh64cOXf5nMerSbYkLgmtuP4e_hnfy-E3nITiFRknGSAFUjsLCcp13Bw1YEUNkplTH2A83TGJufxp4vkYgud9LEw3q2y0_2tTm-0dfdk2K3mcJnnwy_AnIm3nzYZRTjj99D9GMTXS-fxz42fBxNNdQ_fmvjmXeRM6-R1qY3pLBL0OGDhbbvTzlJXsGauLXZxOxptdqXxE_S4g5N41M74KdqyxTP0YNoZzJ-jX-e1d379gUuHR9_zoiSL1vvlCs-vS_LeF4jAM5-mf9WEM-K593LJ7BH-oP2Ffl4QeoR1keHR0keuY8C4GDAjPl1nCfdDz9vsrBX-mtff8MisaosnIEM1HuvcO76_QIvx6eJkQrraC8QkCa2JEUxIG8RZwKTTVOrUSuoci4RxnGvNTATggrswdHAmSWlkhIWTE8AXB4gzo7touygLu4ewFNQByTOXhNpvfjo0aZrILAbsl8lAD1DYL7kyXV5yXx7jSvUOaJfKk8kXzGQqoArINEDv1n2WbVaOO1vTnpKqjzcFDalg07izF_9bL1t1Ql6pUFWRCtQfjDhAybrnDV7-5xcPbrDZ5tcAhVEuYeD9nu_UZhaJR6EAxMUAHa5fg5Lwlh9d2HJVKSYEo3DSHKCXLbduhmaSS8DZr_5zzofo4WQxPVNnH2efX6NH7QWVJKHcR9v19cq-AchWpweNSP4G2jI7QA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Utility+of+amino-terminal+pro-brain+natriuretic+peptide%2C+galectin-3%2C+and+apelin+for+the+evaluation+of+patients+with+acute+heart+failure&rft.jtitle=Journal+of+the+American+College+of+Cardiology&rft.au=van+Kimmenade%2C+Roland+R&rft.au=Januzzi%2C+James+L&rft.au=Ellinor%2C+Patrick+T&rft.au=Sharma%2C+Umesh+C&rft.date=2006-09-19&rft.issn=1558-3597&rft.eissn=1558-3597&rft.volume=48&rft.issue=6&rft.spage=1217&rft_id=info:doi/10.1016%2Fj.jacc.2006.03.061&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0735-1097&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0735-1097&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0735-1097&client=summon |